|
1.
|
|
9 p, 1.5 MB |
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma : updated results from IKEMA, a randomized Phase 3 study
/
Martin, Thomas (University of California at San Francisco, USA) ;
Dimopoulos, Meletios (University of Athens, Greece) ;
Mikhael, Joseph (Translational Genomics Research Institute. City of Hope Cancer Center, Phoenix, USA) ;
Yong, Kwee (University College Hospital, London, UK) ;
Capra, Marcelo (Centro Integrado de Hematologia e Oncologia. Hospital Mãe de Deus, Porto Alegre, Brazil) ;
Facon, Thierry (Lille University Hospital, France) ;
Hajek, Roman (University of Ostrava, Czech Republic) ;
Špička, Ivan (Department of Hematology. 1st Faculty of Medicine. Charles University and General Hospital, Prague, Czech Republic) ;
Baker, Ross (Murdoch University, Perth, Australia) ;
Kim, Kihyun (Sungkyunkwan University School of Medicine, Seoul, South Korea) ;
Martinez, Gracia (Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil) ;
Min, Chang-Ki (The Catholic University of Korea) ;
Pour, Ludek (University Hospital Brno (República Txeca)) ;
Leleu, Xavier (Service d'Hématologie et Thérapie Cellulaire. CHU and CIC Inserm, France) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Koh, Youngil (Seoul National University Hospital, Seoul, South Korea) ;
Suzuki, Kenshi (Japanese Red Cross Medical Center, Tokyo, Japan) ;
Casca, France (Ividata Life Science, Levallois-Perret, France) ;
Macé, Sandrine (Sanofi, R&D, Chilly-Mazarin, France) ;
Risse, Marie-Laure (Sanofi, R&D, Vitry-sur-Seine, France) ;
Moreau, Philippe (University Hospital Hôtel-Dieu, Nantes, France)
Longer-term outcomes with the anti-CD38 antibody isatuximab in combination with carfilzomib-dexamethasone (Isa-Kd) were evaluated in the randomized Phase 3 trial IKEMA (NCT03275285), in a prespecified, follow-up analysis of progression-free survival (PFS, primary study endpoint), final complete response (CR) using Hydrashift Isa immunofixation assay, minimal residual disease (MRD) negativity, and safety. [...]
2023 -  10.1038/s41408-023-00797-8
Blood Cancer Journal, Vol. 13 Núm. 1 (december 2023)
|
|
|
2.
|
|
20 p, 525.5 KB |
Managing hematological cancer patients during the COVID-19 pandemic : an ESMO-EHA Interdisciplinary Expert Consensus
/
Buske, Christian (University Hospital of Ulm (Alemanya)) ;
Dreyling, M. (Department of Medicine III at LMU Hospital) ;
Álvarez Larrán, Alberto (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Apperley, Jane (Imperial College London) ;
Arcaini, Luca (University of Pavia) ;
Besson, Caroline (UVSQ. Inserm. CESP) ;
Bullinger, Lars (Charité - Universitätsmedizin Berlin) ;
Corradini, Paolo (University of Milan) ;
Della Porta, Matteo Giovanni (Humanitas University) ;
Dimopoulos, Meletios (National and Kapodistrian University of Athens) ;
D'Sa, Shirley (University College London Hospitals NHS Foundation Trust) ;
Eich, H.T. (University of Muenster) ;
Foà, R. (Sapienza University) ;
Ghia, P. (Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele) ;
da Silva, M.G. (Portuguese Institute of Oncology) ;
Gribben, J. (Queen Mary University of London) ;
Hajek, Roman (University of Ostrava) ;
Harrison, C. (Guy's and St Thomas' NHS Foundation Trust) ;
Heuser, M. (Hannover Medical School) ;
Kiesewetter, Barbara (Medical University of Vienna) ;
Kiladjian, Jean-Jacques (Université de Paris) ;
Kroeger, Nicolaus (University Hospital Hamburg-Eppendorf) ;
Moreau, Philippe (University Hospital Hotel-Dieu) ;
Passweg, Jakob R. (University Hospital Basel (Basilea, Suïssa)) ;
Peyvandi, Flora (University of Milan) ;
Rea, Delphine (Hôpital Saint-Louis) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Robak, Tadeusz (Medical University of Lodz) ;
San-Miguel, J (Clínica Universidad de Navarra) ;
Santini, Valeria (University of Florence) ;
Sanz, G. (CIBERONC. IS Carlos III) ;
Sonneveld, P. (Erasmus MC Cancer Institute) ;
Von Lilienfeld-Toal, M. (Hans Knöll Institute) ;
Wendtner, Clemens-Martin (Ludwig-Maximilian University) ;
Pentheroudakis, G. (European Society for Medical Oncology) ;
Passamonti, Francesco (University of Insubria)
Background: The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group. [...]
2022 - 10.1016/j.esmoop.2022.100403
ESMO open, Vol. 7 Núm. 2 (april 2022) , p. 100403
|
|
|
3.
|
|
13 p, 861.9 KB |
Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation : The phase III TOURMALINE-MM4 trial
/
Dimopoulos, Meletios (The National and Kapodistrian University of Athens) ;
Špička, I. (Charles University. Faculty of Medicine in Hradec Králové) ;
Quach, H. (St Vincent's Hospital (Sydney)) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Hájek, R. (Department of Hemato-oncology. University Hospital Ostrava. University of Ostrava. Faculty of Medicine) ;
Garg, M. (Leicester General Hospital (Leicester, Regne Unit)) ;
Beksac, M. (Department of Hematology. Ankara University) ;
Bringhen, S. (Division of Hematology. University of Torino. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino) ;
Katodritou, E. (Department of Hematology. Theagenion Cancer Hospital) ;
Chng, W. J. (Department of Hematology-Oncology. National University Cancer Institute. National University Health System. Yong Loo Lin School of Medicine. Cancer Science Institute of Singapore. National University of Singapore) ;
Leleu, Xavier (Pôle Régional de Cancérologie. Department of Haematology. Centre Hospitalier Universitaire La Milétrie-Poitiers) ;
Iida, S. (Department of Hematology and Oncology. Nagoya City University. Graduate School of Medical Sciences) ;
Mateos, M. V. (Hospital Universitario de Salamanca. Centro de Investigación del Cáncer) ;
Morgan, G. (Perlmutter Cancer Center. NYU Langone Health) ;
Vorog, A. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ;
Labotka, R. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ;
Wang, B. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ;
Palumbo, A. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ;
Lonial, S. (Department of Hematology and Medical Oncology. Winship Cancer Institute of Emory University) ;
Universitat Autònoma de Barcelona
PURPOSE Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has generally been limited to immunomodulatory agents. [...]
2020 - 10.1200/JCO.20.02060
Journal of Clinical Oncology, Vol. 38 Núm. 34 (january 2020) , p. 4030-4041
|
|
|
4.
|
|
11 p, 1.3 MB |
Melflufen for relapsed and refractory multiple myeloma
/
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Larocca, Alessandra (Azienda Ospedaliero-Universitaria Città Della Salute E Della Scienza Di Torino. University of Torino) ;
Leleu, Xavier (Department of Hematology. CHU De Poitiers) ;
Hájek, R (Department of Hemato-Oncology. University of Ostrava and Faculty of Medicine. University of Ostrava) ;
Hassoun, Hani (Memorial Sloan Kettering Cancer Center) ;
Rodríguez-Otero, P. (Clínica Universidad de Navarra) ;
Paner, A. (Division of Hematology. Oncology and Stem Cell Transplant. Rush University Medical Center) ;
Schjesvold, F. H. (Oslo Myeloma Center. Oslo University Hospital and K.G. Jebsen Centre for B-Cell Malignancies. University of Oslo) ;
Gullbo, J. (Department of Medical Sciences. Division of Clinical Pharmacology. Uppsala University) ;
Richardson, Paul G.. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Jerome Lipper Multiple Myeloma Center) ;
Universitat Autònoma de Barcelona
Introduction: The overall survival of patients with multiple myeloma has improved with the advent of novel agents; however, multiple myeloma remains incurable. Combinations of standard-of-care agents such as immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies are increasingly used in earlier lines of therapy. [...]
2020 - 10.1080/13543784.2020.1808884
Expert Opinion on Investigational Drugs, Vol. 29 Núm. 10 (february 2020) , p. 1069-1078
|
|
|
5.
|
|
8 p, 354.8 KB |
A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
/
Hájek, R (Faculty of Medicine. University of Ostrava) ;
Pour, L. (University Hospital Brno (República Txeca)) ;
Ozcan, M. (Ankara University School of Medicine) ;
Martin Sánchez, J. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
García Sanz, R. (Hospital Universitario de Salamanca) ;
Anagnostopoulos, Achilles (George Papanicolaou General Hospital (Tessalònia, Grècia)) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cascavilla, N. (Istituto di Ricovero e Cura A Carattere Scientifico (IRCCS)) ;
Terjung, A. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ;
Lee, Y. (Pharmacyclics LLC. an AbbVie Company) ;
Briso, E. M. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ;
Dobkowska, E. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ;
Hauns, B. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ;
Špička, I. (Charles University. Faculty of Medicine in Hradec Králové) ;
Universitat Autònoma de Barcelona
Objective: We evaluated ibrutinib, a once-daily inhibitor of Bruton's tyrosine kinase, combined with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who had received 1-3 prior therapies. [...]
2020 - 10.1111/ejh.13377
European Journal of Haematology, Vol. 104 Núm. 5 (january 2020) , p. 435-442
|
|
|
6.
|
|
8 p, 788.7 KB |
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
/
Hájek, R. (University Hospital Ostrava) ;
Masszi, T. (St László Hospital (Hongria)) ;
Petrucci, M. T. (Sapienza Università di Roma) ;
Palumbo, A. (Università di Torino) ;
Rosiñol, L. (Hospital Clínic i Provincial de Barcelona) ;
Nagler, Arnon. (Chaim Sheba Medical Center (Israel)) ;
Yong, K. L. (University College London Cancer Institute) ;
Oriol, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Minarik, J. (University Hospital Olomouc (Olomouc, República Txeca)) ;
Pour, L. (University Hospital Ostrava) ;
Dimopoulos, Meletios (The National and Kapodistrian University of Athens) ;
Maisnar, V. (Charles University. Faculty of Medicine in Hradec Králové) ;
Rossi, Davide (Amedeo Avogadro University of Eastern Piedmont) ;
Kasparu, H. (Ordensklinikum Linz Elisabethinen) ;
Van Droogenbroeck, J. (AZ Sint-Jan, Brugge, Belgium) ;
Yehuda, D. B. (Hadassah Medical Center, Jerusalem, Israel) ;
Hardan, I. (Meir Medical Center, Kfar-Saba, Israel) ;
Jenner, M. (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ;
Calbecka, M. (Nicolaus Copernicus Hospital, Toruń Poland) ;
Dávid, M. (University of Pécs, Hungary) ;
de la Rubia, Javier (Hospital Universitari i Politècnic La Fe (València)) ;
Drach, J. (Medical University of Vienna) ;
Gasztonyi, Z. (Petz Aladár Megyei Oktató Kórház, Vasvári Pál, Hungary) ;
Górnik, S. (Zamojski Szpital Niepubliczny, Zamosc, Poland) ;
Leleu, Xavier (Hopital Huriez, CHRU, Lille, France) ;
Munder, M. (University Medicine Mainz, Germany) ;
Offidani, M. (Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Italy) ;
Zojer, N. (Center for Oncology, Hematology with Outpatient Department and Palliative Care, Wilhelminenspital, Vienna, Austria) ;
Rajangam, K. (Onyx Pharmaceuticals, Inc.) ;
Chang, Y. L. (Onyx Pharmaceuticals, Inc.) ;
San-Miguel, J. F. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Ludwig, H. (Wilhelminen Cancer Research Institute (Viena, Àustria))
This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). [...]
2017 - 10.1038/leu.2016.176
Leukemia, Vol. 31 (2017) , p. 107-114
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
